CO6280491A2 - Granulacion en humedo que utiliza secuestrante de agua - Google Patents

Granulacion en humedo que utiliza secuestrante de agua

Info

Publication number
CO6280491A2
CO6280491A2 CO10067826A CO10067826A CO6280491A2 CO 6280491 A2 CO6280491 A2 CO 6280491A2 CO 10067826 A CO10067826 A CO 10067826A CO 10067826 A CO10067826 A CO 10067826A CO 6280491 A2 CO6280491 A2 CO 6280491A2
Authority
CO
Colombia
Prior art keywords
trimethoxyphenylamino
oxazin
pyrido
ylamino
pyrimidin
Prior art date
Application number
CO10067826A
Other languages
English (en)
Inventor
Thomas Sun
Ray Lo
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40623940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6280491(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CO6280491A2 publication Critical patent/CO6280491A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Se describen tabletas que comprenden formulaciones estables hidrolíticamente de sal disódica de (6-(5-flúor-2-(3,4, 5-trimetoxifenilamino)pirimidin-4-ilamino) -2,2-dimetil-3-oxo-2H-pirido[3,2-b][1,4]oxazin-4(3H)-il)metil fosfato (compuesto 1) preparado por un proceso de granulación en húmedo.1.- Una formulación granulada en húmedo caracterizada porque comprende agua, una cantidad eficaz de sal disódica de (6-(5-flúor-2-(3,4,5-trimetoxifenilamino) pirimidin-4-ilamino)-2, 2-dimetil-3-oxo-2H-pirido[3,2-b][1,4]oxazin-4(3H)-il)metil fosfato y una cantidad suficiente de un agente secuestrante de agua para inhibir la descomposición de sal disódica de (6-(5-flúor-2-(3,4,5-trimetoxifenilamino)pirimidin-4-ilamino)-2,2-dimetil-3-oxo-2H-pirido[3,2-b][1,4]oxazin-4(3H)-il)metil fosfato, en donde la formulación, después de secado, tiene una densidad en masa suficiente para formar tabletas que tienen una dureza en el intervalo de aproximadamente 6kp hasta aproximadamente 30 kp.2.- La formulación de conformidad con la reivindicación 1, caracterizada porque después de secar la formulación tiene una densidad en masa de entre aproximadamente 0.35 hasta aproximadamente 0.65 g/mL.
CO10067826A 2007-11-07 2010-06-04 Granulacion en humedo que utiliza secuestrante de agua CO6280491A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98623707P 2007-11-07 2007-11-07

Publications (1)

Publication Number Publication Date
CO6280491A2 true CO6280491A2 (es) 2011-05-20

Family

ID=40623940

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10067826A CO6280491A2 (es) 2007-11-07 2010-06-04 Granulacion en humedo que utiliza secuestrante de agua

Country Status (34)

Country Link
US (3) US8263122B2 (es)
EP (1) EP2217241B1 (es)
JP (1) JP5567487B2 (es)
KR (2) KR20150129067A (es)
CN (1) CN101998857A (es)
AU (1) AU2008323938B2 (es)
BR (1) BRPI0820389A2 (es)
CA (1) CA2704474C (es)
CO (1) CO6280491A2 (es)
CR (1) CR11476A (es)
CU (1) CU23915B1 (es)
CY (1) CY1122163T1 (es)
DK (1) DK2217241T3 (es)
DO (1) DOP2010000136A (es)
EA (1) EA020210B1 (es)
EC (1) ECSP10010233A (es)
ES (1) ES2672519T3 (es)
HN (1) HN2010000930A (es)
HR (1) HRP20181174T1 (es)
HU (1) HUE039193T2 (es)
IL (1) IL205204A (es)
LT (1) LT2217241T (es)
MX (1) MX2010004733A (es)
MY (1) MY169761A (es)
NI (1) NI201000078A (es)
NZ (1) NZ585913A (es)
PL (1) PL2217241T3 (es)
PT (1) PT2217241T (es)
RS (1) RS57525B1 (es)
SG (1) SG185961A1 (es)
SI (1) SI2217241T1 (es)
TR (1) TR201807879T4 (es)
UA (1) UA102825C2 (es)
WO (1) WO2009061909A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080223392A1 (en) * 2007-03-14 2008-09-18 L'oreal Process for relaxing or straightening hair
GB0814688D0 (en) 2008-08-12 2008-09-17 Knauf Insulation Thermal insulation product
CA2777225C (en) * 2009-09-07 2019-06-11 Douglas Robert Cleverly Granulated anthelmintic preparations and delivery systems
BR112012020585A2 (pt) * 2010-02-24 2018-04-17 Auspex Pharmaceuticals Inc composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase
PT2736487T (pt) * 2011-07-28 2019-02-13 Rigel Pharmaceuticals Inc Novas formulações de (trimetoxifenilamino) pirimidinilo
US20180296579A1 (en) 2015-04-24 2018-10-18 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
US5763172A (en) * 1992-01-21 1998-06-09 Board Of Regents, The University Of Texas System Method of phosphate ester hydrolysis
US5358652A (en) * 1992-10-26 1994-10-25 Ethyl Petroleum Additives, Limited Inhibiting hydrolytic degradation of hydrolyzable oleaginous fluids
EP1051181B1 (en) * 1997-12-31 2004-03-17 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
US6238677B1 (en) * 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US6716453B1 (en) * 1999-05-20 2004-04-06 Verion, Inc. Method for increasing the active loading of compressible composition forms
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1487419A2 (en) * 2002-03-20 2004-12-22 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20060018972A1 (en) * 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
ITMI20040498A1 (it) * 2004-03-16 2004-06-16 Solvay Solexis Spa Composizioni granulari
BRPI0606318B8 (pt) * 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
US20110237609A1 (en) * 2010-03-29 2011-09-29 Chelsea Therapeutics, Inc. Antifolate compositions

Also Published As

Publication number Publication date
ECSP10010233A (es) 2010-07-30
RS57525B1 (sr) 2018-10-31
CU23915B1 (es) 2013-07-31
CY1122163T1 (el) 2020-07-31
UA102825C2 (ru) 2013-08-27
DOP2010000136A (es) 2010-09-30
US20130189359A1 (en) 2013-07-25
AU2008323938A1 (en) 2009-05-14
KR20150129067A (ko) 2015-11-18
EP2217241A2 (en) 2010-08-18
CR11476A (es) 2010-08-27
CU20100089A7 (es) 2011-10-05
WO2009061909A2 (en) 2009-05-14
HRP20181174T1 (hr) 2018-09-21
HUE039193T2 (hu) 2018-12-28
CA2704474A1 (en) 2009-05-14
MX2010004733A (es) 2010-06-25
MY169761A (en) 2019-05-15
HN2010000930A (es) 2012-11-12
IL205204A0 (en) 2010-12-30
IL205204A (en) 2015-07-30
SI2217241T1 (sl) 2018-10-30
CN101998857A (zh) 2011-03-30
US8263122B2 (en) 2012-09-11
AU2008323938B2 (en) 2014-04-10
KR101663838B1 (ko) 2016-10-07
ES2672519T3 (es) 2018-06-14
KR20100088622A (ko) 2010-08-09
EP2217241B1 (en) 2018-04-25
JP5567487B2 (ja) 2014-08-06
US8652492B2 (en) 2014-02-18
EA201070570A1 (ru) 2010-10-29
CA2704474C (en) 2016-04-26
PL2217241T3 (pl) 2018-11-30
TR201807879T4 (tr) 2018-06-21
PT2217241T (pt) 2018-06-11
BRPI0820389A2 (pt) 2015-05-19
WO2009061909A3 (en) 2009-11-05
US20090123539A1 (en) 2009-05-14
LT2217241T (lt) 2018-09-10
EA020210B1 (ru) 2014-09-30
NI201000078A (es) 2011-05-16
JP2011503010A (ja) 2011-01-27
US20120288543A1 (en) 2012-11-15
US8372415B2 (en) 2013-02-12
DK2217241T3 (en) 2018-08-06
SG185961A1 (en) 2012-12-28
NZ585913A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
CO6280491A2 (es) Granulacion en humedo que utiliza secuestrante de agua
AR110010A2 (es) Composición farmacéutica formulada en una forma de dosis única de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo
CR7899A (es) Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa
SV2004001418A (es) Formulaciones farmaceuticas de 5,7,14-triazaciclo 10.3.1.0.2,11.04,9) -hexadeca-2(11),3,5,7,9-pentaeno" ref.pc 23248
HRP20040323C1 (hr) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance
ECSP14018630A (es) Formulaciones farmacéuticas novedosas
BRPI0620063B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
PL1998762T3 (pl) Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku
MY153728A (en) Foamable fluoride oral care composition
AR076864A1 (es) Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos
AR037560A1 (es) Formulacion de altas dosis de ibandronato
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
AR025879A1 (es) Granulaciones de celulosa hidrolizada de sales de farmacos
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
EA201070626A1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
AR040306A1 (es) Capsula de liberacion controlada para la administracion de formulacion liquida
HN2006023741A (es) " formulaciones de liberacion prolongada de principios activos de zolpidem hemitartrato"
AR074689A1 (es) Formulaciones farmaceuticas de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral. proceso de preparacion
GR1004660B (el) Βελτιωμενες φαρμακευτικες συνθεσεις του τριυδρικου αλενδρονικου νατριου και μεθοδοι παρασκευης τους
ES2170645B1 (es) Forma farmaceutica solida de administracion oral de una sal de metamizol soluble en agua, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
CO5330617A1 (es) Nueva forma solida de dosificacion oral de 5-[2-etoxi-5 (4-metilpiperazin-1-il sulfonil) fenil]-1,6-dihidro-1-metil- 3-propilpirazolo[4,3-d]pirimidin-7-ona citrato y proceso para su fabricacion
EA200401357A1 (ru) Болеутоляющая композиция для перорального применения с регулируемым высвобождением опиоида
RS49979B (sr) Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju
UY28575A1 (es) Composiciones farmacéuticasa sólidas que comprende el ácido bis (e)-7-(4-(4-fluorfenil-6 -isopropil-2- (metil (metilsulfonil) amino) pirimidin- 5-il) -3r,5s)-3,5- dihidroxo- ............

Legal Events

Date Code Title Description
FC Application refused